ACSL4 and idiopathic pulmonary fibrosis: More recently, a selective small-molecule ACSL4 inhibitor, AS-252424, exhibited both anti-ferroptotic and anti-fibrotic effects in experimental settings, further underscoring the therapeutic potential of directly modulating lipid metabolism in the context of IPF (152).